糖痹通胶囊治疗糖尿病周围神经病变55例临床观察

目的　观察糖痹通治疗糖尿病周围神经病变的临床疗效。方法　 110例糖尿病周围神经病变患者随机分为 2组 ,在常规控制血糖基础上 ,治疗组 5 5例予糖痹通胶囊 ,每次 3粒 ,每日 3次口服 ;对照组5 5例予弥可保 ,每次 5 0 0 μg ,每日 3次口服。 2组均 2个月为 1个疗程。观察 2组临床疗效及治疗前后肌电图变化情况。结果　治疗组显效率为 5 8.18% ,总有效率 92 .72 %。对照组显效率 38.18% ,总有效率 70 .90 %。 2组比较 ,显效率和总有效率均有显著性差异 (P <0 .0 5 ,P <0 .0 1) ;治疗后 ,治疗组正中神经和腓总神经运动神经传导速度 (MNCV)与感觉神经传导速度 (SNCV)与治疗前比较均有显著性差异 (P <0 .0 5 ,P <0 .0 1) ,与对照组比较亦有显著性差异 (P <0 .0 1)。结论　糖痹通能明显改善糖尿病周围神经病变 (DNP)的临床症状 ,提高神经传导速度 ,治疗糖尿病神经病变临床疗效显著 ,且无任何毒、副作用

Observation of Tangbitong Capsule on the treatment of peripheral neuropathy of diabetes mellitus

Objective To observe the therapeutic effect of Tangbitong Capsule on peripheral neuropathy of diabetes mellitus. Methods 110 patients with peripheral neuropathy of diabetes mellitus were randomly divided into two groups. 55 patients in control group were treated by Methylcobal, 0.5mg one time, three times a day. 55 patients in treatment group were treated by Tangbitong capsule, 3 pills one time, three times one day for two months. The therapeutic effect and EMG were observed before and after treatment in both groups. Results The apparent rate and total effective rate in treatment group (58.18%, 92.72%) were higher than those in control group (38.18%, P<0.05; 70.90%, P<0.01). There were obvious differences of the MNCV and SNCV of media nerve and Tbil nerve between before and after treatment in both groups (P<0.05, P<0.01). Conclusions Tangbitong capsule could treat peripheral neuropathy of diabetes mellitus and improve the clinical symptoms and enhance the nervous conduction velocity of peripheral neuropathy of diabetes mellitus.